{
  "docId": "019de075-746f-7643-8ae7-19646171e75b",
  "docSlug": "e49fd8f0d5e7ac656caa3720c9a74f92",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 28,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-746f-7643-8ae7-19646171e75b/16",
  "deckHref": "/decks/019de075-746f-7643-8ae7-19646171e75b",
  "deckJsonHref": "/decks/019de075-746f-7643-8ae7-19646171e75b.json",
  "deckAnchorHref": "/decks/019de075-746f-7643-8ae7-19646171e75b#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.23,
        "x": 0.77,
        "y": 0.29
      },
      "kind": "list",
      "text": "Imdusiran was generally safe and well-tolerated after completing dosing in 41 patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "64d0b5ac-aceb-43f4-a449-3260a9658326",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.23,
        "x": 0.27,
        "y": 0.29
      },
      "kind": "list",
      "text": "Discontinuation of both imdusiran and NA-therapy results in sustained reduction in HBsAg and HBV DNA in 7 of 9 patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "846c8d50-bd2e-4399-b5c6-be118bd1d6fc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.23,
        "x": 0.02,
        "y": 0.29
      },
      "kind": "list",
      "text": "Imdusiran provided robust and comparable HBsAg declines regardless of dose, dosing interval, HBeAg or DNA status",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c4d01994-593f-4ca9-87ff-b94a1bcdc5e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.23,
        "x": 0.52,
        "y": 0.29
      },
      "kind": "list",
      "text": "Imdusiran results in HBV-specific T-cell immune restoration and decrease of exhausted T-cells in some patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef4ab671-4760-406f-bdff-d55f01568b8e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.15,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "* Data previously presented",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b05d20a7-749a-4602-94ab-b5c7d50f7a65",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.55,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "AB-729-001 Clinical Trial Key Takeaways",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "97e4f51d-ff2b-44a8-bf63-ac4501522101",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "40c2a3b1-058f-44d6-a497-86b737f02660",
      "evidence": "The slide contains a list of bullet points summarizing key takeaways from a clinical trial.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 16,
      "from": 9,
      "beatId": "8558af21-b173-40d9-bee7-cbb86e4f3ca4",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The deck presents Arbutus Biopharma's pipeline, including Imdusiran, AB-161, and AB-101, as a promising approach to treating HBV",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 16,
      "from": 9,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "cf0f4444-bb37-4efd-b316-e8da602c5aea",
      "evidence": "The deck presents data and results from clinical trials for Imdusiran and other pipeline assets",
      "position": 1,
      "objective": "Showcase Arbutus Biopharma's pipeline as a solution to the HBV problem",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.6,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}